Setrobuvir
Based on 1 Customer Validation
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.98%
- CAS No.: 1071517-39-9
- 화학식: C25H25FN4O6S2
- 분자량:560.62
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
>100 μM
Compound: 2c
|
Cytotoxicity against human HuH7 cells assessed as GAPDH release
Cytotoxicity against human HuH7 cells assessed as GAPDH release
|
[PMID: 19818610] |
| Huh-7 | CC50 |
100 μM
Compound: 38, ANA-598
|
Cytotoxicity against human HuH7 cells
Cytotoxicity against human HuH7 cells
|
[PMID: 22516671] |
| Huh-7 | EC50 |
3 nM
Compound: 38, ANA-598
|
Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication by replicon assay
Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication by replicon assay
|
[PMID: 22516671] |
| Huh-7 | EC50 |
52 nM
Compound: 38, ANA-598
|
Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication by replicon assay
Antiviral activity against Hepatitis C virus genotype 1a infected in human HuH7 cells assessed as inhibition of viral replication by replicon assay
|
[PMID: 22516671] |
In Vitro
Setrobuvir (ANA598) is a non-nucleoside inhibitor that binds to the palm pocket of the HCV polymerase and has an EC50 against HCV genotype 1b/Con1-containing subgenomic replicons in the nanomolar range. Setrobuvir appears to inhibit both de novoinitiated RNA synthesis and primer extension, and its activity is unchanged by the presence of mutations that modify the activity of thumb-binding non-nucleoside inhibitors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1071517-39-9
-
Appearance Solid
-
분자량 560.62
-
화학식 C25H25FN4O6S2
-
Color White to off-white
-
SMILES
CS(=O)(NC1=CC=C(C2=C1)N=C(C3=C(O)[C@]4([H])[C@@](C5)([H])CC[C@@]5([H])[C@]4([H])N(CC6=CC=C(F)C=C6)C3=O)NS2(=O)=O)=O
-
Synonyms
ANA598
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
In Vitro:
DMSO : 252.5 mg/mL (450.39 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yi G, et al. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother. 2012;56(2):830‐837. [Content Brief]
[2]. Elfiky AA. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silicoperspective [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1‐9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7837 mL | 8.9187 mL | 17.8374 mL | 44.5935 mL |
| 5 mM | 0.3567 mL | 1.7837 mL | 3.5675 mL | 8.9187 mL | |
| 10 mM | 0.1784 mL | 0.8919 mL | 1.7837 mL | 4.4593 mL | |
| 15 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL | 2.9729 mL | |
| 20 mM | 0.0892 mL | 0.4459 mL | 0.8919 mL | 2.2297 mL | |
| 25 mM | 0.0713 mL | 0.3567 mL | 0.7135 mL | 1.7837 mL | |
| 30 mM | 0.0595 mL | 0.2973 mL | 0.5946 mL | 1.4864 mL | |
| 40 mM | 0.0446 mL | 0.2230 mL | 0.4459 mL | 1.1148 mL | |
| 50 mM | 0.0357 mL | 0.1784 mL | 0.3567 mL | 0.8919 mL | |
| 60 mM | 0.0297 mL | 0.1486 mL | 0.2973 mL | 0.7432 mL | |
| 80 mM | 0.0223 mL | 0.1115 mL | 0.2230 mL | 0.5574 mL | |
| 100 mM | 0.0178 mL | 0.0892 mL | 0.1784 mL | 0.4459 mL |
Setrobuvir Related Classifications
HY-13247 Related Classifications
Powered by Bioz